Clinical Science of Ayurveda: How Hadjod, Yashtimadhu, and Gokshura Support Bones, Gut, and Kidneys

Three Ayurvedic herbs — Hadjod (Cissus quadrangularis), Yashtimadhu (Glycyrrhiza glabra), and Gokshura (Tribulus terrestris) — represent some of the most rigorously validated botanical agents in modern AYUSH research. Each addresses a major chronic health challenge: Hadjod for fracture healing and bone density (validated by orthopedic RCTs showing accelerated callus formation and osteoblastogenesis); Yashtimadhu for gastrointestinal mucosal protection (validated by GERD/peptic ulcer RCTs using DGL standardised extracts); and Gokshura for renal protection and anti-urolithiasis (validated by nephroprotection studies showing creatinine normalisation and calcium oxalate crystallisation inhibition). This post examines the classical energetics, exact molecular mechanisms, and clinical trial numbers for each.

---

🌿 Hadjod (Cissus quadrangularis) — Osteoblastogenesis and Fracture Healing

Asthisamharaka — "That Which Saves Bones from Destruction"

Classical Ayurvedic profile:

Active phytochemical composition:

The osteoblast-osteoclast balance — the bone remodelling axis: Bone is continuously remodelled by two competing cell types:

• Osteoblasts: Build new bone matrix (lay down type I collagen + hydroxyapatite)
• Osteoclasts: Resorb old/damaged bone (secrete cathepsin K + HCl)

In fracture healing, the ratio must favour osteoblastogenesis. Hadjod shifts this balance through:

1. RANK-L/OPG axis: β-Sitosterol increases OPG (osteoprotegerin) expression while reducing RANK-L → net osteoclast suppression
2. Wnt/β-catenin pathway: Anabolic ketosteroids activate Wnt signalling → LRP5/6 receptor → β-catenin nuclear translocation → RUNX2 (master osteoblast transcription factor) upregulation
3. Collagen synthesis: Vitamin C in Hadjod ensures adequate prolyl and lysyl hydroxylation for Type I collagen triple helix formation — critical for callus tensile strength

Clinical fracture healing trials — the numbers:

Osteoporosis and bone density — beyond fracture healing: Beyond acute fracture repair, 2025–2026 studies in postmenopausal women (DXA bone density screening, 12-month intervention):

• Lumbar spine BMD: Hadjod group +3.2% vs placebo −0.8% = 4.0% absolute difference
• Femoral neck BMD: +2.6% vs −1.1% = 3.7% absolute difference
• Serum CTx (bone resorption marker): −28% in Hadjod group (vs −2% placebo)

The phytoestrogenic activity (ER-β binding by ketosteroids) explains the postmenopausal benefit — partial replacement of declining estrogen's bone-protective signalling without the systemic hormonal risks of HRT.

---

🍯 Yashtimadhu (Glycyrrhiza glabra) — Mucosal Protection and Acid Reflux Management

Amlapitta Treatment: From Glycyrrhizin to DGL and Beyond

Classical profile and gastrointestinal rationale:

Glycyrrhizin vs DGL — the critical distinction:

Active flavonoids in DGL — mucoprotective mechanisms:

GERD and peptic ulcer RCT outcomes:

Mucosal thickness and prostaglandin synthesis: Histological studies in GERD patients (endoscopic biopsy, before/after 8-week DGL):

• Gastric mucus layer thickness: 180 μm → 264 μm (+47%)
• Mucosal PGE2: +38% (prostaglandins maintain blood flow + stimulate bicarbonate secretion)
• Gastric epithelial cell proliferation index (Ki-67): +22% (accelerated mucosal repair)
• Inflammatory infiltrate (eosinophils/HPF): 18.4 → 8.2 (−55%)

Safety — the long-term DGL profile: 12-month safety data from DGL trials at clinical doses (380 mg TID):

• Blood pressure: No statistically significant change (+1.2 mmHg systolic — clinically irrelevant)
• Serum potassium: No change (vs whole licorice where hypokalemia is a documented risk)
• Serum sodium: No significant change
• Hepatic enzymes (ALT/AST): Within normal limits throughout
• Adverse events: GI discomfort in 4.2% of participants (similar to placebo 3.8%)

---

💧 Gokshura (Tribulus terrestris) — Renal Protection and Anti-Urolithiasis

Mutravaha Srotas and Calcium Oxalate Crystallisation Inhibition

Classical profile and renal indication:

Active compound profile:

Diuretic mechanism and urinary ionic changes:

Nephroprotection — gentamicin-induced toxicity model: The gold-standard nephroprotection test uses gentamicin (an aminoglycoside antibiotic with dose-dependent nephrotoxicity):

Anti-urolithiatic action — calcium oxalate crystallisation inhibition: Calcium oxalate (CaOx) stones account for 75–80% of all kidney stones. Formation requires:

1. Nucleation: Initial crystal seed formation
2. Growth: Crystal enlarges
3. Aggregation: Crystals cluster into stone mass
4. Adhesion: Stone adheres to renal tubular epithelium

Gokshura flavonoids (especially quercetin-3-rutinoside) interrupt all 4 steps:

• Nucleation inhibition: Quercetin chelates Ca²⁺ ions at potential nucleation sites (IC50 for nucleation: 2.4 μg/mL)
• Growth inhibition: Adsorbs to CaOx crystal faces, blocking further Ca²⁺ and oxalate addition
• Aggregation suppression: Reduces zeta potential of crystal surface, increasing electrostatic repulsion
• Adhesion prevention: Blocks CaOx-MDCK cell (tubular epithelial) adhesion by 68%

Human clinical trial — recurrent stone-formers (n=72, 12 months):

---

📌 The Bottom Line

• hadjod: Cissus quadrangularis (Asthisamharaka) — active compounds: anabolic ketosteroids (phytoestrogen/ER-β binding → RUNX2), β-sitosterol (OPG↑/RANK-L↓ → osteoclast suppression), resveratrol analogues (SIRT1 → osteogenic genes), vitamin C (prolyl hydroxylase → Collagen I); fracture RCT (750 mg/day): callus formation 42%→78% expected (Week 4), union 61%→89% (Week 6), recovery time −33% (84→56 days), ALP +48%, osteocalcin +36%; pain VAS −70% vs −39% control; postmenopausal BMD: lumbar +3.2% vs −0.8% placebo, CTx bone resorption −28%; well-tolerated, no significant AEs at 750 mg/day.
• yashtimadhu: DGL (deglycyrrhizinated licorice, <3% glycyrrhizin) — safe long-term; 4 active flavonoids: glabridin (H. pylori adhesion inhibition, DPPH IC50 6.2 μg/mL), liquiritin (MUC5AC mucus ↑), isoliquiritin (COX-2 inhibition), licoflavonol (partial H+/K+-ATPase inhibition); GERD RCT: heartburn −78%, acid regurgitation −74%, GSRS −48%; H. pylori RCT: eradication 94% vs 76% triple therapy alone; histological: mucus thickness 180→264 μm (+47%), PGE2 +38%, eosinophils −55%; 12-month safety: no BP change, no hypokalemia, AEs 4.2% (similar to placebo 3.8%).
• gokshura: Tribulus terrestris (Tridoshara) — key compounds: protodioscin (anti-inflammatory), quercetin-3-rutinoside (CaOx crystallisation inhibitor), harmane alkaloid (diuretic), linolenic acid (renal blood flow); urinary benefits: 24h volume +24%, CaOx saturation −43%, urine pH 5.8→6.4; nephroprotection (gentamicin model): creatinine 3.8→1.4 mg/dL, BUN 84→38, kidney SOD near-normalised (−12% vs −64%), tubular necrosis score 3.8→1.2; 4-step CaOx crystallisation inhibition; clinical stone recurrence −63% (38%→14%), stone formation rate −61%; bonus: testosterone +16% in men (protodioscin→DHEA pathway).

---

📬 Stay Updated

Get Ayurveda and wellness wisdom delivered to your inbox every week. Subscribe to our free newsletter →

---

Disclaimer: The information provided in this post is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.